Sabby Management’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Sabby Management’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-190,000	Closed	-$602K	–	228
2017 Q2	$602K	Sell	190,000 -10,000	-5%	-$31.6K	0.04%	127
2017 Q1	$680K	Buy	200,000 +100,000	+100%	+$282K	0.04%	153
2016 Q4	$288K	Buy	100,000 +50,000	+100%	+$178K	0.02%	230
2016 Q3	$294K	Buy	+50,000	New	+$175K	0.01%	257
2015 Q1	–	Sell	-145,919	Closed	-$2.4K	–	336
2014 Q4	$2.4K	Sell	145,919 -114,081	-44%	-$1.32M	0.08%	111
2014 Q3	$3.31K	Buy	260,000 +107,006	+70%	+$1.61M	0.13%	76
2014 Q2	$3.45M	Buy	152,994 +101,484	+197%	+$1.84M	0.15%	74
2014 Q1	$1.46M	Buy	+51,510	New	+$1.91M	0.08%	123

Other funds holding DRNA

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Sabby Management's DRNA Position: Q3 2017 in Review

Sabby Management sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q3 2017, closing a stake of 190,000 shares — an estimated $602K sold.

Sabby Management first reported a position in DRNA in Q1 2014 and held it in 8 quarters. The position peaked at $3.45M in Q2 2014. 37 funds tracked by Wall St. Rank hold DRNA as of Q3 2017.

Sabby Management reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
Sabby Management sold 190,000 Dicerna Pharmaceuticals, Inc. shares in Q3 2017, an estimated $602K.
Sabby Management first reported a position in Dicerna Pharmaceuticals, Inc. in Q1 2014 and held it in 8 quarters.
Sabby Management's Dicerna Pharmaceuticals, Inc. position peaked at $3.45M in Q2 2014.
37 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q3 2017.

Based on Sabby Management's 13F filing for Q3 2017, filed 14 Nov 2017.